What is Certara?
Certara operates at the intersection of advanced software engineering and clinical science, providing a comprehensive suite of AI-driven platforms and scientific consulting services. By leveraging proprietary biosimulation technologies, the company enables pharmaceutical and biotechnology organizations to predict drug behavior with unprecedented accuracy. This capability is critical throughout the entire drug development lifecycle, from initial discovery and preclinical modeling to the high-stakes environment of clinical trials and regulatory submissions. By optimizing these processes, Certara helps its clients reduce the time and cost associated with bringing life-saving therapies to market, effectively transforming how the industry approaches therapeutic development and market access.
How much funding has Certara raised?
Certara has raised a total of $1.4B across 4 funding rounds:
Stock Offering
$668M
Stock Offering
$310M
Private Equity
$449M
Private Equity
$8.6M
Stock Issuance/Offering (2020): $668M with participation from Undisclosed
Stock Issuance/Offering (2021): $310M, investors not publicly disclosed
Private Equity (2022): $449M supported by Arsenal Capital Partners
Private Equity (2026): $8.6M, investors not publicly disclosed
Key Investors in Certara
Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity firm specialized in investments in middle-market industrial growth and healthcare companies, utilizing a build-for-tomorrow philosophy to support innovation-rich businesses.
Undisclosed Investors
Undisclosed Investors
What's next for Certara?
With the recent influx of capital, Certara is well-positioned to accelerate its R&D initiatives and expand its footprint in the global healthcare technology landscape. The company is expected to focus on enhancing its AI-driven predictive modeling capabilities, which are increasingly vital for navigating the complexities of modern regulatory environments. As the industry shifts toward more personalized medicine and data-centric clinical strategies, Certara's commitment to MIDD will likely serve as a primary growth engine. Investors and stakeholders are closely watching how the firm will deploy these resources to further integrate its biosimulation tools into the workflows of global pharmaceutical giants, potentially setting new standards for efficiency and safety in drug development.
See full Certara company page
